title: Site-specific modification of ED-B-targeting antibody using intein-fusion technology.
abstract: BACKGROUND
  A promising new approach in cancer therapy is the use of tumor specific antibodies coupled to cytotoxic agents. Currently these immunoconjugates are prepared by rather unspecific coupling chemistries, resulting in heterogeneous products. As the drug load is a key parameter for the antitumor activity, site-specific strategies are desired. Expressed protein ligation (EPL) and protein trans-splicing (PTS) are methods for the specific C-terminal modification of a target protein. Both include the expression as an intein fusion protein, followed by the exchange of the intein for a functionalized moiety.
  
  
  RESULTS
  A full-length IgG specific for fibronectin ED-B was expressed as fusion protein with an intein (Mxe GyrA or Npu DnaE) attached to each heavy chain. In vitro protocols were established to site-specifically modify the antibodies in high yields by EPL or PTS, respectively. Although reducing conditions had to be employed during the process, the integrity or affinity of the antibody was not affected. The protocols were used to prepare immunoconjugates containing two biotin molecules per antibody, attached to the C-termini of the heavy chains.
  
  
  CONCLUSIONS
  Full-length antibodies can be efficiently and site-specifically modified at the C-termini of their heavy chains by intein-fusion technologies. The described protocols can be used to prepare immunoconjugates of high homogeneity and with a defined drug load of two. The attachment to the C-termini is expected to retain the affinity and effector functions of the antibodies.
authors.affiliation: Bayer Healthcare Research Center, Aprather Weg 18a, 42113 Wuppertal, Germany.
authors.forename: Sina
authors.initials: S
authors.lastname: Möhlmann
authors.forename: Peter
authors.initials: P
authors.lastname: Bringmann
authors.forename: Simone
authors.initials: S
authors.lastname: Greven
authors.forename: Axel
authors.initials: A
authors.lastname: Harrenga
mesh_terms: D000595:Amino Acid Sequence; D004591:Electrophoresis, Polyacrylamide Gel; D005353:Fibronectins / Q000276:immunology*; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D047668:Inteins / Q000235:genetics*; D008969:Molecular Sequence Data; D015202:Protein Engineering / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D020040:Trans-Splicing
chemical_list: C067625:FN1 protein, human; D005353:Fibronectins; D018796:Immunoconjugates; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins